ClinicalTrials.gg
CompletedNCT06139666Updated Nov 5, 2026

The Effect of Liposomal Bupivacaine Nerve Block (Exparel) in Rotator Cuff Surgery

A Phase 4 interventional study of Exparel Injectable Solution and Bupivacaine Injectable Solution in Rotator Cuff Tears, Postoperative Pain and Opioid Use, sponsored by Cooper Norcross Health. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Cooper Norcross Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.
  • Registered 4 years after the study started (first participant enrolled Jul 2019, registered Jul 2023).
Updated Nov 5, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Liposomal Bupivacaine in Rotator Cuff Injuries — none open to participants now, none under way, none of them phase 3. Liposomal Bupivacaine · Rotator Cuff Injuries.

Enrollment
2nd of 10
128 · median 59
Started
2019
with 4 others
Phase 4
6 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Cooper Norcross Health

Among the 10 studies testing Liposomal Bupivacaine in Rotator Cuff Injuries, this one is the 2nd largest by enrollment, is one of 5 that started in 2019, is one of 6 in phase 4, and was the 10th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

None of the 10 studies testing Liposomal Bupivacaine in Rotator Cuff Injuries is open now. The open studies under Rotator Cuff Injuries, anywhere →

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing Liposomal Bupivacaine in Rotator Cuff Injuries as a file.
02

Study summary

The goal of this clinical trial is to investigate if there is a difference in pain after an arthroscopic rotator cuff surgery when a nerve block is performed with liposomal bupivacaine versus the standard treatment of bupivacaine alone.

The main question aims to answer if patients who receive liposomal bupivacaine have better pain control and lower postoperative opioid consumption compared to bupivacaine alone.

Participants be randomized to either the control group to receive a standard interscalene block with bupivacaine (25 cc of bupivacaine) or the experimental group to receive similar dosing of liposomal bupivacaine mixed with bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine). Data will be prospectively collected and the data from the experimental group will be compared to the control group at the completion of the study period.

Read the detailed description

Nerve blocks are typically performed for shoulder surgery for perioperative pain control. This is performed in the shoulder using an interscalene block, which is localized between the anterior and middle scalene muscles in the neck and provides analgesia to the clavicle, shoulder and its capsule and some to the arm. Using this method allows for conscious sedation to be used over general anesthesia, mitigating the dangers associated with the latter, and also comes with the added benefit of providing improved postoperative analgesia.

Bupivacaine is the medication that is typically used for these procedures to provide the analgesia in these sensory patterns. It works by binding to the intracellular portion of voltage-gated sodium channels, preventing depolarization of the nerve and subsequently inhibiting transmission of nerve signals. Typical interscalene blocks have been shown to have pain control for 6-8 hours and have an effect decreasing opioid usage for up to 24 hours. Liposomal bupivacaine, trade name Exparel, was recently introduced as an alternative to drugs such as bupivacaine, but boasting a longer duration of action. In Exparel, bupivacaine is stored in liposomes, which allows for a controlled and longer duration of release of the analgesia-producing molecules. This allows nerve blockades to last longer, allowing for longer prevention of neurotransmitter release. It was initially only approved for local infiltration, most notably in the joint capsule for a total knee arthroplasty. Recently however, it was FDA approved for interscalene blocks, opening up a new avenue for pain control modalities. No studies have yet been performed comparing the difference in analgesia provided by liposomal bupivacaine compared to bupivacaine alone in the context of interscalene blocks in rotator cuff surgery

Nerve blocks with local anesthetics has been proven safe and effective for perioperative pain control. With recent talks of healthcare providers decreasing narcotic usage postoperatively in an effort to prevent opiate addiction, longer acting nerve blocks are becoming more and more appealing. By increasing the duration of a nerve blockade, postoperative narcotic use may be significantly decreased, with minimal risk of harm to the patient.

This is a prospective, double-blinded (surgeon and patient) randomized therapeutic trial. Patients will either receive a standard interscalene block with bupivacaine (25 cc of bupivacaine) or will receive similar dosing of liposomal bupivacaine mixed with bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), which has recently been approved and instituted. These blocks (both) are currently in practice at the study institution and the decision of which to use is currently up to the anesthesiologist. It is current practice that every patient undergoing a rotator cuff surgery is offered a nerve block. Data will be prospectively collected and the data from the experimental group will be compared to the control group at the completion of the study period.

Patents will present for surgery and follow up postoperatively as they would routinely for rotator cuff surgery or shoulder arthroscopy. The anesthesiologist administering the injection will be not be blinded to the mixture of injection (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.

When discharged home, patients will be asked to keep a log of their narcotic consumption, as well as bringing in their prescription vial to the postoperative follow up and also logging other medications that are consumed during this time period. They will also be asked to log their pain scores in the form of a standardized VAS pain scale form that they will fill out daily until their first follow up visit.

03

Conditions studied

  • Rotator Cuff Tears
  • Postoperative Pain
  • Opioid Use

Keywords

  • Rotator Cuff Repair
  • Postoperative Pain Control
  • Orthopedic Surgery
  • Anesthesia
  • Nerve block
  • bupivacaine
  • Liposomal Bupivacaine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients above 18 years of age
  • Undergoing rotator cuff surgery or shoulder arthroscopy using an interscalene block

Exclusion criteria

Exclusion Criteria:

  • Patients with preexisting (COPD) or respiratory issues precluding the use of an interscalene block
  • Pregnant women, women nursing infants
  • Patients with preexisting liver disease
  • Patients unwilling to have interscalene block performed
  • Patients allergic to bupivacaine, liposomal bupivacaine, or any ingredients contained within the two drugs listed
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Active comparator
    Control- Bupivacaine Alone

    patients will receive a standard interscalene block with bupivacaine alone (25 cc of bupivacaine)

    Drug: Bupivacaine Injectable Solution

  • Experimental
    Study- Exparel

    patients will receive an interscalene block with Exparel solution, which is an extended-release formulation of bupivacaine consisting of 10cc liposomal bupivacaine mixed with 15cc bupivacaine. This is approved and used at the study institution

    Drug: Exparel Injectable Solution

Interventions

  • DrugLiposomal BupivacaineStudies of Liposomal BupivacaineLiposomal Bupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients randomized to this arm will receive an interscalene block with Exparel solution, an extended-release formulation of bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), approved for use at the study institution. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will be not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care. After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count.

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients randomized to this arm will receive a standard interscalene block consisting of 25 cc of bupivacaine alone. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care. After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count.

06

What researchers measure

Primary outcomes

  1. Use of pain medications

    Patients will be asked to bring their bottle of pain medication prescribed after surgery to their first office visit so a narcotic pill count can be performed. Patients will record their pain pill consumption every day for 2 weeks in a study journal. The journal containing the pill count will be collected at the 2 week visit in the office. Opioid consumption will be quantified as milligram of opioid equivalents (MME).

    Time frame: 2 week postoperative visit

Secondary outcomes

  1. Pain severity

    Patients will rate their pain using the VAS pain scale survey. The visual analog scale (VAS) is a pain rating scale first used by Hayes and Patterson in 1921. Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm). These results will be recorded every day for the first 2 weeks in a study journal. The journal containing the VAS scores will be collected at the 2 week visit in the office. The VAS will be administered again at the 6 week and 12 week visit.

    Time frame: Every day for the first 2 weeks, and a one-time survey at the 6 week and 12 week visit.

07

Study locations

1 site
08

References and documents

Publications

  • Kim DH, Liu J, Beathe JC, Lin Y, Wetmore DS, Kim SJ, Haskins SC, Garvin S, Oxendine JA, Ho MC, Allen AA, Popovic M, Gbaje E, Wu CL, Memtsoudis SG. Interscalene Brachial Plexus Block with Liposomal Bupivacaine versus Standard Bupivacaine with Perineural Dexamethasone: A Noninferiority Trial. Anesthesiology. 2022 Mar 1;136(3):434-447. doi: 10.1097/ALN.0000000000004111. PubMed 35041742 ↗
  • Wiederhold BD, Garmon EH, Peterson E, Stevens JB, O'Rourke MC. Nerve Block Anesthesia(Archived). 2023 Apr 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK431109/ PubMed 28613761 ↗
  • Lonner JH, Scuderi GR, Lieberman JR. Potential utility of liposome bupivacaine in orthopedic surgery. Am J Orthop (Belle Mead NJ). 2015 Mar;44(3):111-7. PubMed 25750943 ↗
  • Vyas KS, Rajendran S, Morrison SD, Shakir A, Mardini S, Lemaine V, Nahabedian MY, Baker SB, Rinker BD, Vasconez HC. Systematic Review of Liposomal Bupivacaine (Exparel) for Postoperative Analgesia. Plast Reconstr Surg. 2016 Oct;138(4):748e-756e. doi: 10.1097/PRS.0000000000002547. PubMed 27673545 ↗
  • Kaye AD, Armstead-Williams C, Hyatali F, Cox KS, Kaye RJ, Eng LK, Farooq Anwar MA, Patel PV, Patil S, Cornett EM. Exparel for Postoperative Pain Management: a Comprehensive Review. Curr Pain Headache Rep. 2020 Oct 23;24(11):73. doi: 10.1007/s11916-020-00905-4. PubMed 33098008 ↗
  • Fedorka CJ, Tornberg HN, Rivera-Pintado C, Gentile PM, Russo D, Boniello M, Hunter K, Desai R, Soni D, Kleiner MT, Dodson G. Liposomal Bupivacaine + Bupivacaine Versus Bupivacaine Interscalene Nerve Block Effect on Pain After Rotator Cuff Repair: A Randomized Control Trial. J Am Acad Orthop Surg. 2026 Aug 15;34(16):e2216-e2225. doi: 10.5435/JAAOS-D-25-01002. Epub 2025 Dec 24. PubMed 41468585 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jun 2024, 58 months.

Of 21 phase 4 interventional studies under Rotator Cuff Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's 58 months is above that.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2025 → Dec 2025, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Nov 18, 2023
StartActual
Jul 11, 2019
Primary completionActual
Jun 1, 2024
CompletionActual
Dec 24, 2025was Jun 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Nov 5, 2026
Study completion
Jun 1, 2025→Dec 24, 2025 (actual)
Nov 5, 2026
Enrollment
160 (estimated)→128 (actual)
Nov 5, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41468585 ↗
Nov 5, 2026
Sponsor
The Cooper Health System→Cooper Norcross Health
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Enrolling by invitation→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41468585 ↗
    Study completion Jun 1, 2025→Dec 24, 2025 (now actual)
    Enrollment 160 (estimated)→128 (actual)
    Sponsor The Cooper Health System→Cooper Norcross Health
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06139666
Lead sponsor
Cooper Norcross Health
Responsible party
Catherine Fedorka MD (Orthopaedic Surgeon, Assistant Professor of Orthopaedic Surgery, Assistant Program Director, Orthopaedic Surgery Residency Program, Cooper Norcross Health) — Principal investigator
First posted
Nov 18, 2023
Start date
Jul 11, 2019
Primary completion
Jun 1, 2024
Completion
Dec 24, 2025
Last update
Nov 5, 2026

Study contacts

Catherine J Fedorka, MD
principal investigator · Cooper Norcross Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion